Skip to main content

Evaluating the Effects of a 14-Day Oral Chemotherapy Dispensing Protocol on Adherence, Toxicity, and Cost

Audiocasts - Original Research
Shardae Young, PharmD, BCPS
Clinical Pharmacy Specialist
Oncology
at VA Texas Valley Coastal Bend Health Care System
Harlingen,TX.
Shardae Young, PharmD, BCPS, Clinical Pharmacy Specialist, Oncology, VA Texas Valley Coastal Bend Health Care System, Harlingen,TX, discusses the clinical significance of her study, “Evaluating the Effects of a 14-Day Oral Chemotherapy Dispensing Protocol on Adherence, Toxicity, and Cost.”
Related Items
Impact of Hyperglycemia During Immune Checkpoint Inhibitor Treatment for Advanced Non–Small Cell Lung Cancer: A Retrospective, Single-Center Study
JHOP - June 2026 Vol 16, No 3 published on February 25, 2026 in Original Research, Checkpoint Inhibitors, Adverse Events, Lung Cancer
Management Patterns and Perceived Educational Needs Related to Cancer Therapy Cardiovascular Toxicities for Cardio-Oncology Providers
JHOP - June 2026 Vol 16, No 3 published on February 19, 2026 in Original Research, Adverse Events, Drug–Drug Interaction
Risk for Vincristine-Induced Adverse Events With Aprepitant in Pediatric Patients With Rhabdomyosarcoma
JHOP - April 2026 Vol 16, No 2 published on January 20, 2026 in Original Research, Adverse Events, Chemotherapy, Drug–Drug Interaction
Infusion-Related Reactions Associated With Nivolumab and Pembrolizumab: A Case Series Analysis
JHOP - June 2026 Vol 16, No 3 published on January 8, 2026 in Original Research, Checkpoint Inhibitors, Infusion Issues, PD-1 Inhibitors
Impact of Universal Pegaspargase Premedication on Substitution Rates and Adverse Events
JHOP - August 2026 Vol 16, No 4 published on January 8, 2026 in Original Research, Adverse Events, Pediatric Cancer, Acute Lymphoblastic Leukemia
Evaluation of Initial Weight-Based Tacrolimus Dosing After Allogeneic Hematopoietic Stem Cell Transplant
JHOP - April 2026 Vol 16, No 2 published on January 7, 2026 in Original Research, Adverse Events, Transplant
Letermovir Prophylaxis After Stem Cell Transplant in Pediatric Patients Aged Younger than 12 Years
JHOP - April 2026 Vol 16, No 2 published on January 2, 2026 in Original Research, Pediatric Cancer, Transplant
Analysis of Ifosfamide-Associated Encephalopathy Between 2 Formulations in Adults With Hematologic Cancer
JHOP - December 2025 Vol 15, No 6 published on December 1, 2025 in Original Research, Adverse Events
A Survey of Biosimilar Adoption Across Oncology Pharmacy Practices
JHOP - December 2025 Vol 15, No 6 published on December 1, 2025 in Original Research, Biosimilars
Evaluation of Serious Immune-Related Adverse Event Incidence in 200-mg Versus 400-mg Pembrolizumab Regimens
JHOP - December 2025 Vol 15, No 6 published on December 1, 2025 in Original Research, Adverse Events, Immunotherapy